ArticleJournal of cellular and molecular medicine2026
TFAP2A-Induced Upregulation of LncRNA NUTM2A-AS1 Promotes LUAD Progression Through a miR-409-5p/SLC35F2 Regulatory Axis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Long non-coding RNAs (LncRNAs) play pivotal roles in lung adenocarcinoma (LUAD) progression. However, the upstream transcriptional regulation and downstream mechanisms of LncRNA NUTM2A-AS1 in LUAD remain largely unexplored. The expression levels of NUTM2A-AS1, TFAP2A, miR-409-5p and SLC35F2 in LUAD tissues and cell lines were analysed using public databases and qRT-PCR. The biological functions of this axis in LUAD cells were evaluated through CCK-8, Transwell and apoptosis assays. The molecular interactions among TFAP2A, NUTM2A-AS1, miR-409-5p and SLC35F2 were validated via chromatin immunoprecipitation (ChIP), dual-luciferase reporter and RNA immunoprecipitation (RIP) assays. Both NUTM2A-AS1 and TFAP2A were significantly upregulated in LUAD and correlated with poor prognosis. Mechanistically, the transcription factor TFAP2A directly bound to the NUTM2A-AS1 promoter to activate its transcription. Functionally, NUTM2A-AS1 promoted LUAD cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT), while suppressing apoptosis. Furthermore, NUTM2A-AS1 may function as a competing endogenous RNA-like regulator by interacting with miR-409-5p, thereby upregulating the expression of the solute carrier family member SLC35F2. Rescue assays demonstrated that SLC35F2 knockdown attenuated the oncogenic phenotypes induced by TFAP2A or NUTM2A-AS1, while miR-409-5p restoration suppressed SLC35F2 expression and cell-cycle progression. Our study supports a TFAP2A/NUTM2A-AS1/miR-409-5p/SLC35F2 regulatory model that contributes to LUAD progression. These findings suggest that the TFAP2A/NUTM2A-AS1/miR-409-5p/SLC35F2 axis contributes to LUAD progression and may provide potential biomarkers and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.